California-based clinical-stage biotechnology company Adcentrx Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for the company's Investigational New Drug (IND) application for ADRX-0405 for the treatment of select advanced solid tumours.
ADRX-0405 is a next-generation antibody-drug conjugate (ADC) composed of a humanised IgG1 antibody targeting six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a cell surface protein that is upregulated in prostate cancer and certain other cancers, yet has limited expression in healthy tissue.
Adcentrx says that its proprietary i-Conjugation technology platform is an important component in the design of ADRX-0405.
The planned first-in-human Phase 1a/b clinical trial of ADRX-0405 is an open-label, multicentre, non-randomised dose escalation and dose expansion study. It will involve patients with advanced solid tumours, including metastatic castration resistant prostate cancer. Primary objectives will be to characterise the safety and tolerability and to determine the optimal dose of ADRX-0405. The company anticipates the first patient to be enrolled in the fourth quarter of 20244, with an estimated initial data readout in the fourth quarter of 2025.
Sanofi and Orano partner to advance radioligand therapies
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies